Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
Go back to Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China| (NASDAQ: VOR) | Delayed: 14.73 +0.25 (1.73%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.48 | 52 Week High | $ | |||
| Open | $14.48 | 52 Week Low | $ | |||
| Day High | $15.19 | P/E | N/A | |||
| Day Low | $14.48 | EPS | $ | |||
| Volume | 104,272 | |||||
